Company Filing History:
1 out of 230 
1 out of 10 Years Active: 2025
Title: Matias Antonio Avila Zaragoza: Innovator in mRNA Therapy for Acute Intermittent Porphyria
Introduction: Matias Antonio Avila Zaragoza, an accomplished inventor based in Pamplona, Spain, has made significant contributions to the field of medicine through his innovative work. With a focus on mRNA therapy, his research addresses critical health challenges, particularly in the treatment of Acute Intermittent Porphyria (AIP).
Latest Patents: Matias holds a patent for "Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria." This patent outlines a groundbreaking invention that utilizes mRNA therapy to treat AIP. The therapy involves administering mRNA that encodes human porphobilinogen deaminase (PBGD), along with its isoforms, functional fragments, and fusion proteins. Encapsulated in lipid nanoparticles (LNPs) for efficient delivery, this innovation aims to restore deficient levels of PBGD expression and activity in patients, effectively reducing the toxic metabolites association with the condition, namely porphobilinogen (PBG) and aminolevulinate (ALA).
Career Highlights: Throughout his career, Matias Antonio Avila Zaragoza has been associated with notable companies, including ModernaTX, Inc. and Fundación Para La Investigación Médica Aplicada. His work in these institutions has positioned him as a key player in advancing mRNA technology and its applications in treating various medical conditions.
Collaborations: In his journey as an inventor, Matias has collaborated with esteemed professionals such as Paolo Martini and Stephen G. Hoge. These partnerships have contributed to the depth and breadth of his research, further enhancing the impact of his inventions in the medical field.
Conclusion: Matias Antonio Avila Zaragoza exemplifies the spirit of innovation in medicine through his pioneering work in mRNA therapy. His patent addressing acute intermittent porphyria not only showcases his expertise as an inventor but also holds the potential to transform the lives of patients affected by this condition. With a commitment to research and collaboration, Matias continues to push the boundaries of what is possible in therapeutic development.